Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Valsartan Plus Chlorthalidone vs Monotherapy in Hypertension
NCT01850160Phase 3Completed
- Sponsor
- Farma de Colombia
- Start
- Apr 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in hypertension (HTN) comparing Valsartan + Chlorthalidone, Valsartan and Chlorthalidone (3 arms). Primary endpoint: Safety and Efficacy of the fixed-dose combination treatment at 12 weeks. Started Apr 2013; status: completed.
02
Drugs
valsartanchlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT01850160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850160.